← Back to Screener
enVVeno Medical Corporation Common Stock (NVNO)
Price$12.08
Favorite Metrics
Price vs S&P 500 (26W)-72.31%
Price vs S&P 500 (4W)-14.37%
Market Capitalization$7.92M
All Metrics
Book Value / Share (Quarterly)$41.36
P/TBV (Annual)1.31x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-23.74
Price vs S&P 500 (YTD)0.24%
Gross Margin (TTM)100.00%
Net Profit Margin (TTM)-5483.33%
EPS (TTM)$-33.19
10-Day Avg Trading Volume0.01M
EPS Excl Extra (TTM)$-33.19
EPS (Annual)$-1.29
ROI (Annual)-52.18%
Gross Margin (Annual)100.00%
Net Profit Margin (5Y Avg)-7032.74%
Cash / Share (Quarterly)$43.01
ROA (Last FY)-48.94%
EBITD / Share (TTM)$-35.15
ROE (5Y Avg)-65.39%
Operating Margin (TTM)-4461.11%
Cash Flow / Share (Annual)$-23.74
P/B Ratio0.29x
P/B Ratio (Quarterly)0.24x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-117.55x
ROA (TTM)-56.01%
EPS Incl Extra (Annual)$-1.29
Current Ratio (Annual)13.58x
Quick Ratio (Quarterly)13.29x
3-Month Avg Trading Volume0.02M
52-Week Price Return-85.71%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.63
P/S Ratio (Annual)263.96x
Asset Turnover (Annual)0.01x
52-Week High$196.70
Operating Margin (5Y Avg)-6266.24%
EPS Excl Extra (Annual)$-1.29
CapEx CAGR (5Y)-51.16%
26-Week Price Return-63.56%
Quick Ratio (Annual)13.29x
13-Week Price Return0.09%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)13.58x
Enterprise Value$4.854
Asset Turnover (TTM)0.03x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-25433.33%
Cash / Share (Annual)$43.01
3-Month Return Std Dev101.19%
Net Income / Employee (TTM)$-1
ROE (Last FY)-52.18%
Net Interest Coverage (Annual)-87.25x
EPS Basic Excl Extra (Annual)$-1.29
Receivables Turnover (TTM)2.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-33.19
Receivables Turnover (Annual)2.00x
ROI (TTM)-60.88%
P/S Ratio (TTM)43.99x
Pretax Margin (5Y Avg)-7056.77%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$4.09
Price vs S&P 500 (52W)-120.81%
Year-to-Date Return4.19%
5-Day Price Return5.88%
EPS Normalized (Annual)$-1.29
ROA (5Y Avg)-54.58%
Net Profit Margin (Annual)-25433.33%
Month-to-Date Return15.50%
Cash Flow / Share (TTM)$-2.12
EBITD / Share (Annual)$-1.28
Operating Margin (Annual)-25600.00%
ROI (5Y Avg)-64.31%
EPS Basic Excl Extra (TTM)$-33.19
P/TBV (Quarterly)2.03x
P/B Ratio (Annual)0.24x
Inventory Turnover (TTM)9.33x
Pretax Margin (TTM)-5483.33%
Book Value / Share (Annual)$41.36
Price vs S&P 500 (13W)-2.78%
Beta1.16x
P/FCF (Annual)87.99x
Revenue / Share (TTM)$0.00
ROE (TTM)-60.88%
52-Week Low$8.67
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
2.17
2.17
2.17
2.17
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
NVNOenVVeno Medical Corporation Common Stock | 43.99x | — | 100.00% | -4461.11% | $12.08 |
SYKStryker Corporation | 5.17x | 11.84% | 64.57% | 19.43% | $338.34 |
BSXBoston Scientific Corp. | 4.58x | 15.16% | 69.01% | 18.00% | $60.99 |
MMM3M Company | 3.21x | -4.97% | 39.92% | 18.55% | $151.40 |
MDLNMedline Inc. Class A common stock | 2.20x | — | 26.44% | 7.78% | $48.26 |
BDXBecton, Dickinson and Co. | 2.06x | 6.32% | 46.42% | 12.15% | $158.64 |
RMDResMed Inc. | 6.07x | 11.72% | 60.85% | 33.70% | $226.14 |
DXCMDexCom, Inc. | 5.33x | 19.33% | 62.09% | 19.56% | $64.62 |
WSTWest Pharmaceutical Services, Inc. | 6.29x | 7.44% | 35.91% | 19.03% | $278.00 |
PODDInsulet Corporation | 5.19x | 24.53% | 71.63% | 12.92% | $200.87 |
PENPenumbra, Inc. | 9.24x | 20.16% | 67.14% | 13.48% | $329.71 |
About
enVVeno Medical Corp develops bioprosthetic venous valve replacements to treat venous disease. The company's lead product, VenoValve, is a surgical replacement currently in a U.S. pivotal trial, while its pipeline includes enVVe, a non-surgical transcatheter option. Both products are designed to restore valve function and improve blood circulation in the legs.